People | July 11, 2022
Piramal Pharma strengthens board by inducting three new board members
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
